TCRVβ6 CDR2 peptide

TCRVβ6 CDR2 peptide is a synthetic peptide derived from the complementarity-determining region 2 (CDR2) of the variable beta chain (Vβ6) of the human T cell receptor (TCR). This class of peptides is designed to modulate immune responses by targeting specific autoreactive or pathogenic T cells. The mechanism involves vaccination with these peptides to induce regulatory or tolerogenic immune responses, potentially reducing pathogenic Th1 activity and promoting beneficial Th2 responses. Such approaches have been investigated in autoimmune diseases like multiple sclerosis and rheumatoid arthritis, where vaccination with specific TCR-derived peptides can alter disease-associated immune profiles[1][2]. The development and use of these peptides are primarily research-based, focusing on their immunomodulatory potential rather than as approved pharmaceutical drugs.

Other names

T cell receptor V beta 6 complementarity-determining region 2 peptideTCR Vβ6 CDR2 peptide